



The Association between Toll-like Receptor 7 and Hepatitis C Virus in a Sample of Iraqi Rheumatoid Arthritis Patients

Dunya Muyad Ahmed* Dunya Fareed Salloom

Biology Department, Science College, University of Baghdad, Baghdad, Iraq.

***Corresponding Author: E-mail:** dunyascience@sc.uobaghdad.edu.iq

Abstract

Background: Rheumatoid arthritis (RA) is one of the chronic inflammatory autoimmune diseases that included articular and joints infections. Viral infection and immunity had been suggested to play a role in the pathogenesis of autoimmune diseases. **Objectives:** The present study designed to estimate the association among RA, Hepatitis C virus (HCV) infections and the role of innate immunity expressed by toll-like receptor-7 (TLR-7) as a possible triggering factor in the sera and blood samples of 47 RA patients. **Results:** The findings of the present study demonstrated that 18 of the 47th RA samples were positive for anti-HCV IgM and IgG antibodies, and 13 of the 18th HCV IgG and IgM seropositive samples were positive for HCV-RNA by using RT-PCR technique. Also, the findings revealed a significant association between RA, HCV infections and TLR-7 serum level in the studied groups. There was a significantly increased level of TLR-7 in the RA group (103.0 ± 73.8 ng/ml) compared to controls (72.9 ± 36.8 ng/ml). **Conclusion:** These findings concluded that hepatitis C virus infection and TLR-7 might have a role in RA pathogenesis.

Keywords: *Autoimmune disease, Rheumatoid arthritis, Hepatitis C virus, Innate immunity, Toll-like receptor-7.*

Introduction

Rheumatoid arthritis (RA) is a progressive autoimmune disease of the unknown etiology that affecting 2-3 times more prevalent in females than in males [1]. The disease characterized by long-lasting inflammation primarily affects joints rendering them swollen, deformed, and painful with movement limitation especially wrists, fingers, ankles and feet typically in a symmetrical pattern, a characteristic not found in other forms of arthritis [2].

RA is a multi-factorial disease, resulting from the interference between both the genetic (50-60%) and the environmental factors [3]. Several environmental factors had been involved in RA pathogenesis include socioeconomic status, smoking, diet, infectious agents and hormonal factors [4, 5].

Viral infection has been proposed to be a trigger factor of autoimmune diseases such as hepatitis C virus (HCV). HCV is a single-stranded RNA without a DNA intermediate in its replicative cycle; therefore, the viral genomic sequences cannot be combined with

the host genome. Much evidence mentions that the HCV infection results from the chronic stimulation of the immune system that assists in increasing the clonal B-lymphocyte [6, 7]. HCV infections have been associated with several autoimmune and rheumatologic disorders. The most common extrahepatic rheumatologic symptoms that include arthralgia, pruritus, myalgia, paresthesia, and sicca syndrome [8]. These extrahepatic manifestations of HCV infection are significant in disease diagnosis and treatment [9].

Much of extra-hepatic symptomatology in HCV can be due to chronic immune complex disease [10]. Toll-like receptors (TLRs) are transmembrane protein structures expressed by innate immune system cells; these transmembrane protein structures recognize the invading microbes, such activate signaling pathways that commence the immune and the inflammatory responses to destroy the invaders. In addition, TLRs belong to the family of pathogen recognition receptors, consider an essential part of the

innate immune response, and detects conserved pathogen-associated molecular patterns (PAMPs) of the invader's components such as bacteria, viruses, parasites, fungi, and protozoa [10]. TLRs have been involved in the pathogenesis of several autoimmune diseases such as RA, systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) [11, 12]. The abnormal expression of TLRs may be associated with sepsis and autoimmune diseases such as (rheumatoid arthritis, lupus erythematosus, and type 1 diabetes), TLR7 is the receptor that recognizes single-stranded viral mRNA, and such finding highlights the possible involvement of viruses in RA pathogenesis [13].

Although not fully investigated, the RNA of invaders occur in the synovial compartment and it was demonstrated that there is an increased expression level of TLR-7 in the synovium of RA patients compared to healthy controls [11]. HCV considered as one of the immunogenic triggers the immune responses.

The intrinsic components of the virus presumably lead to activate the innate immune system that effectively limits viral replication. The earliest response to HCV is by interferon (IFN) type's production, which is a critical cytokine, establish an antiviral state and link the innate and adaptive immune systems [14, 15].

TLR-7 is expressed primarily in the endosome-lysosome membrane of each of B lymphocytes, plasmacytoid dendritic cells (pDCs), hepatic natural killer cells, and virally infected hepatocytes. The endosomal proteases in these cells digest HCV molecules such as uncoated and released viral ssRNA that is generally recognized by TLR7 [15, 16]. Therefore, the aim of the present study is to assess the presence of viral infection and part of innate immunity represented by TLR-7 serum level in the pathogenesis of RA patients.

Materials and methods

Patients

Forty-Seven Iraqi RA patients (35 females and 12 males) were enrolled in this study with age mean \pm standard deviation (SD) (49.9 ± 13.3 years). They referred to the Consultant Clinic at the Department of Rheumatology, Baghdad Teaching Hospital

during the period October 2016 -- June 2017 for diagnosis and treatment. The diagnosis depended on the clinical symptoms and the clinical laboratory examinations according to the 2010 American College of Rheumatology/ European League against Rheumatology for RA [17]. In addition to patients, 28 apparently healthy individuals (20 females and 8 males) with no clinical symptoms or a family history for RA were enrolled in the study as a control group with the age mean \pm SD matched patients group (44.7 ± 11.6 years). The study was permitted by the local ethics committee of the Health ministry, Baghdad Teaching Hospital. In addition to the informed permission that was obtained from the study volunteers.

Methods

Five milliliters of venous blood was dropped from all the study volunteer groups. The withdrawn blood amount was divided into two parts, the first part (4 milliliters) was separated in a polyethylene test tubes to collect serum for serological examination, the blood left to clot at room temperature (25°C), then the tubes were centrifuged at $1207 \times g$ for 10 minutes, and the sera were separated in Eppendorf tubes.

While the second part (1 milliliter) was kept in an ethylenediaminetetraacetic acid tube (EDTA) for molecular examination. The sera of studied groups were tested to detect the presence of anti-CCP IgG antibody (EUROIMMUN company, Germany), anti-Hepatitis C Virus IgG and IgM antibodies (Foresight / USA, CUSABIO Biotech Co./ China), and to assess the level of TLR-7 (Shanghai Yehua Biological Technology Co. / China) by using ELISA technique.

Confirmatory test was also performed by using conventional PCR technique; the amplification of HCV-RNA was performed to confirm the virus existence in HCV seropositive samples for RA patients. The detecting RNA of Hepatitis C Virus for the seropositive for IgG and IgM antibodies samples was by using a reverse-transcriptase PCR technique. The HCV-RNA was extracted by using the commercially ZR Viral RNA Kit™ (Zymo Research Corp./ USA) according to the manufacturer's protocol.

The concentration and purification of extracted RNA were quantified by using the

Nanodrop spectrophotometer (Quawell technology Inc. / USA) with the wavelength (230, 260 and 280 nm). Specific forward and reverse oligonucleotide primer sequences for RT-PCR were designed for the amplification of HCV-RNA by conventional RT-PCR (forward primer: GTG AGG AAC TAC TGT CTT CAC G; reverse primer: ACT CGC AGG CAC CCT ATC AGG) (Integrated DNA Technologies company/ USA) [18], Primers compatibility search was performed by using the Basic Local Alignment Search Tool (BLAST) of the National Center Biotechnology Information (NCBI) online program. For producing a dsDNA frequent of 262 base pair (bp), the primers were dissolved and diluted according to the manufacturer's protocol.

A PCR mixture was set up in a total volume of 25 µl for the reaction mixture that involved 1.5 µl of a previously extracted RNA (~50 ng/µl), 0.5 µl of RT master mix, 5 µl of a PCR master mix, 2 µl of (10 Pmol/µl) of each primer, 0.5 µl of dNTPs, and 15.5 µl of sterile de-ionized free nuclease water. The HCV-RNA was converted to cDNA and then to dsDNA in the same reaction, the conditions of an RT-PCR for an HCV-RNA were one

cycle at 50 °C for 30 minutes to convert the ssRNA to a ssDNA (cDNA), once cycle at 95 °C for 15 minutes to complete the other strand of the DNA that result as a dsDNA, 40 cycles at (95 °C for 1 minute, 55 °C for 1 minute, 72 °C for 1 minute), and one cycle at 72 °C for 10 minutes. The PCR products were separated to 2% agarose gel (Promega/ USA) electrophoresis stained with 0.02 µl/ml of Red Safe® stain (Intron biotechnology com./ Korea) and 5 µl of 50-10000 bp DNA ladder (Kappa biosystem/ USA), then visualized by using an ultraviolet light transilluminator.

Statistical Analysis

The data were analyzed by using the IBM SPSS computer program version 24 and expressed as mean ± SD, one-way ANOVA table, and Duncan test. OR, 95% CI, Pearson's X^2 and two-tailed Fischer exact probability were calculated by using WinPepi computer program V. 3.08. The statistical significance level was set at $P < 0.05$ [19].

Results

In the present study, Table 1 showed the level of anti-CCP IgG antibody in the sera of RA patients and healthy control groups.

Table 1: Anti-CCP value in the studied groups

Anti-CCP antibody level RU/ml (mean ± SD)	
RA patients	Healthy control
31.9±15.2 ^a	2.3±0.9 ^c

Similar letters referred to non-significant differences ($P > 0.05$).
Different letters referred to significant differences ($P < 0.05$).

Such, Table 2 showed the level of TLR-7 in the sera of

RA patients and the healthy control groups.

Table 2: Toll-like receptors7 level in the studied groups

TLR-7 level ng/m (mean ± SD)	
RA patients	Healthy control
103±73.8 ^a	72.9±36.8 ^b

Similar letters referred to non-significant differences ($P > 0.05$).
Different letters referred to significant differences ($P < 0.05$).

According to the present study, the results of anti-HCV IgM antibody assessment demonstrated that 11(23.4%) was seropositive in RA patients and 36 (76.6%) were seronegative for anti-HCV IgM

antibody. In contrast, 0(0%) was seropositive and 28(100%) was seronegative in the healthy control group for anti-HCV IgM antibody, as shown in Table 3.

Table 3: Anti-HCV IgM antibody percentage distribution in the studied groups

Anti-HCV IgM	Groups				OR (95% CI)	X ²	P
	Healthy control		RA patients				
	Observed subjects	%	Observed subjects	%			
Positive	0	0	11	23.4	18.0	7.6	5.2x10 ⁻³
Negative	28	100	36	76.6			
Total	28	100	47	100			

OR: Odd ratio, 95% CI: 95% confidence interval, X^2 : Pearson's chi-square test, P : Two-tailed Fischer exact probability.

Anti-HCV-IgG antibody was also determined. In the RA patient group, 7(14.9%) was seropositive and 40(85.1%) was seronegative.

In contrast, 0(0%) was seropositive and 28(100%) was seronegative in the healthy control group, as shown in Table 4.

Table 4: Anti-HCV IgM antibody percentage distribution in the studied groups

Anti-HCV IgM	Groups				OR (95% CI)	X²	P
	Healthy control		RA patients				
	Observed subjects	%	Observed subjects	%			
Positive	0	0	7	14.9	10.6	4.6	0.041
Negative	28	100	40	85.1			
Total	28	100	47	100			

OR: Odd ratio, 95% CI: 95% confidence interval, X^2 : Pearson's chi-square test, *P*: Two-tailed Fischer exact probability.

In addition, the results of molecular detection of HCV in the sera of RA group in the current study demonstrated that 13 samples from the 18th seropositive samples for anti-HCV IgG and IgM antibodies were positive for HCV-RNA by using RT-PCR technique. Figure 1 showed the electrophoresis fractionation of the amplified RT-PCR products of the

5'untranslated region (UTR) of HCV genome that was located at (262 bp) on a 2% agarose gel stained with Red Safe® stain at 10 volt/cm² for 1 hour in 1x Tris-Borate-EDTA buffer and visualized under UV. light. Thus, there may be a causal association might exist between HCV and RA in some patients [20].




Figure 1: Agarose gel electrophoresis of the PCR product for detecting the 5'UTR of HCV-RNA (the band size is 262 bp) that fractionated on a 2% agarose gel (Promega/ USA) stained with Red Safe® stain (INTRON Biotechnology com./ Korea) at 10 volt/cm² for 1 hour in 1x Tris-Borate-EDTA buffer (Promega/ USA). L: DNA ladder 50-10000bp (Kappa biosystem/ USA), lane 1-13 is the PCR product band (262 bp) that visualized under UV. Light.

Discussion

The results of anti-CCP IgG antibody level in the studied groups showed that there was a significantly increased level ($P < 0.05$) in RA group compared to the healthy control group (31.9 ± 15.2 RU/ml vs. 2.3 ± 0.9 RU/ml, respectively). This finding matched the findings of other studies that referred to the significantly increased level ($P < 0.05$) of anti-CCP IgG antibody in RA patients compared to the control group. Therefore, the detection of anti-CCP IgG antibody is important because it is a specific biomarker for RA [21] appears as a result to an epitope

response that modified by a hormonally controlled enzyme, peptidyl arginine deiminase that converts arginine to citrulline [22]. Such, the anti-CCP IgG antibody activates the complement system through classical and alternative pathways and leads to a strong indication of their pathophysiologic involvement [23]. The increased synthesis of CCP has been shown to be as a result of apoptosis and inflammation induced cellular death (necroinflammation). This process is depending on inflammation rather than

disease dependent [24]. This contradiction in anti-CCP IgG antibody levels may due to racial and genetic backgrounds [25]. While other authors referred these differences to the presence of different subsets of anti-CCP antibodies directed against different epitopes in citrulline containing molecules [26].

The effect of HLA alleles on the levels of serum anti-CCP IgG antibody in which RA patients with HLA-DRB1 have a higher level than RA patients lacking this epitope [27]. Also, the Results indicate that the serum level of TLR-7 was significantly higher ($P < 0.05$) in RA group compared to control group (103.0 ± 73.8 ng/ml *vs.* 72.9 ± 36.8 ng/ml, respectively). These findings in agreement with the results of a previous study that demonstrated to the high serum level of TLR-7 that expressed in patients with RA [28].

Such, other studies detected that the elevated levels of TLR-7 in the synovium of RA patients were higher than osteoarthritis (OA) patients or healthy controls [11, 29]. Although the mechanisms behind the increased expression levels of TLR-7 have not been clarifying yet; but probably due to the activation of TLR7 by their specific ligand probably single strand RNA (ssRNA) [30, 31] that was demonstrated as an HCV in the current study.

Such, viral infection leads to activate antigen presenting cells (APCs) that are plentiful in the RA synovial compartment, the APCs such as macrophages and DCs have an important role in RA pathogenesis [32]. While Yang *et al.* (2014) [33] reported that the expression level of TLR 3 and 7 was decreased in HCV infections due to the upregulation of microRNA- 758 (miR-758) that inhibit the expression of TLR 3 and 7 in patients with HCV infections. Previous studies demonstrated that TLR7 has a role in

inhibiting HCV infection as a part of innate immunity by decreasing the HCV-RNA in HCV infected patients [34].

The decreasing mechanism of TLR7 was by inducing interferon- α production and activating interferon regulatory factors such as INF- α B [35]. Also, The findings of HCV IgM and IgG showed a highly OR value (18.0 and 10.0, respectively), these referred that HCV is a strong risk factor triggers RA etiology.

These findings were agreed with previous studies indicated that the prevalence of anti-HCV antibodies in RA patients was 20% higher than the reported prevalence in Egypt (14.7%) [36,39]. The presence of HCV infection in the RA has been well documented, and a genetic background for this association has been postulated. HLA-DR4 is significantly increased in those patients with HCV infection who develop autoimmune diseases [40].

Also, HCV weakens the innate immunity pathways that limit HCV replication such as IFNs and generating a chronic inflammatory state that causes persistent liver injury [41]. In addition, the 5' UTR of the HCV genome is generally used for HCV detection and genotyping assays because it has a highly conserved region contains specific polymorphisms that distinguish the six major genotypes and some subtypes of HCV [42]. Similarly, the detection of HCV genomes by RT-PCR technique was performed by the amplification of a 262 bp of the 5' UTR domain of the HCV genome by using one-step reverse transcription-PCR [43, 44].

Conclusion

HCV infections and TLR-7 level seem to be related to the pathogenesis of RA.

References

- 1- Rudan I, Sidhu S, Papana, A, Meng SJ, Xin Wei, Wang, W, Campbell-Page RM, Demaio AR, Nair H, Sridhar D and Theodoratou E (2015) Prevalence of rheumatoid arthritis in low-and middle-income countries: A systematic review and analysis. *Journal of global health*, 5: 010-409.
1. Boman A, Kokkonen H, Ärlestig L, Berglin E, Rantapää-Dahlqvist S (2017) Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. *Clinical Rheumatology*, 11:1-8.
2. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. *Autoimmunity Reviews*, 4: 130-136.
3. Tobon GJ, Youinoua P and Saraux A (2010) The environment, geo-epidemiology and autoimmune disease: Rheumatoid

- arthritis. *Journal of Autoimmunity*, 35: 10-14.
4. Ferri C (2008) Mixed cryoglobulinemia. *Orphanet J. Rare Dis.*, 3:25.
5. Salih KM, Al-Mosawy WF (2016) Influence of blood transfusion rate on some clinical manifestations in β -thalassemia major patients. *J. Contemp. Med. Sci.*, 2: 15-19.
6. Cacoub P, Poynard T, Ghillani P, *et al.* Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. *Arthritis Rheum.* 1999; 42: 2204-2212.
7. Hassan HF, Khashman, BM, Abdul Qader, OA and Izzat, AW. Assessment of Cox2 and CMV in patients with chronic HCV infection. *J Contemp Med Sci.* 2017; 3:182-185.
8. Ali A, Zein NN (2005) Hepatitis C infection: a systemic disease with extrahepatic manifestations. *Cleve Clin. J. Med.*, 72:1005-1008.
9. Pawlotsky JM, Ben Yahia M, Andre C, *et al* (1994) Immunological disorders in C virus chronic active Hepatitis: A prospective case-control study *Hepatology*, 19: 841-848.
10. Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor signals in innate immune defense. *Nat Rev Immunol.*, 7: 179-90.
11. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR (2005) The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and co-stimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. *Arthritis Rheum.*, 52: 2313-2322.
12. Broen JC, Bossini-Castillo L, van Bon L, Vonk MC, Knaapen H, Beretta L, Rueda B, Hesselstrand R, Herrick A, Worthington J, Hunzelman N, Denton CP, Fonseca C, Riemekasten G, Kiener HP, Scorza R, Simeón CP, Ortego-Centeno N, Gonzalez-Gay MA, Airò P, Coenen MJ, Martín J, Radstake TR (2012) A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. *Arthritis Rheum.*, 64: 264-271.
13. Schaaf B, Luitjens K, Goldmann T, van Bremen T, Sayk F, Dodt C, Dalhoff K and Droemann D (2009) Mortality in human sepsis is associated with downregulation of Toll-like receptor 2 and CD14 expression on blood monocytes. *Diagn Pathol.*, 4: 12-19.
14. Zhang YL, Guo YJ, Bin L, Sun SH (2009) Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. *J. Hepatol.*, 51: 29-38.
15. Abdel-Raouf TA, Ahmed A, Zaki WK, Abdella HM, Abo Zid M (2014) Study of toll-like receptor 7 expression and interferon α in Egyptian patients with chronic hepatitis C Infection and Hepatocellular Carcinoma. *Egyptian Journal of Medical Human Genetics*, 15: 387-392.
16. Askar E, Ramadori G, Mihm S (2010) Toll-like receptor 7 rs179008/ Gln11Leu gene variants in chronic hepatitis C virus infection. *J. Med. Virol.*, 82: 1859-1868.
17. Funovits J, Aletaha D, Bykerk V *et al* (2010) The 2010 American College of Rheumatology/European league against rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. *Annals of the Rheumatic Diseases*, 69: 1589-1595.
18. El Awady MK, Azzazy HM, Fahmy AM, Shawky SM, Baderldin NG, Yossef SS, Omran MH, Zekri A-RN, Goueli SA (2009) Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patient's response to therapy. *World J. Gastroenterol.*, 15:1480-1486.
19. Steel RG, Torries JH (1980) *Principal and Procedures of Statistics. A biometrical approach* 2nd Ed. McGraw - Hill Book Company. New York USA.
20. Sawada T, Hirohata S, Inoue T, Ito K (1991) Development of RA often hepatitis C virus infection. *Arth. Rheum.*, 34: 1620-1621.
21. Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, Emad Y (2013) Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody in Juvenile Idiopathic Arthritis (JIA): Correlations with Disease Activity and Severity of Joint Damage (a Multicenter Trial). *Joint, Bone, Spine.*, 80: 38-43.

22. Van Venrooij WJ, Hazes JM, Visser H (2002) Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. *Neth. J. Med.*, 60: 383-388.
23. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, Huizinga TW, Toes RE (2009) Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. *Arthritis Rheum.*, 60: 1923-1931.
24. Vannini A, Cheung K, Fusconi M, Stammen-Vogelzangs J, Drenth JP, Dall'Aglio AC, Bianchi FB, Bakker-Jonges LE, van Venrooij WJ, Pruijn GJ, Zendman AJ (2007) Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?. *Ann Rheum. Dis.*, 66: 511-516.
25. Mimori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. *Intern Med.*, 44(11): 1122-6.
26. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. *Clin. Chem.*, 47: 1089-1093.
27. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. *Arthritis Rheum.*, 50: 2113-2121.
28. Huang QQ, Pope RM (2009) Role of toll-like receptors in rheumatoid arthritis. *Curr Rheumatol. Rep.*, 11: 357-364.
29. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, Joosten LA, van den Berg WB (2004) Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon- γ . *Arthritis Rheum.*, 50: 3856-3865.
30. Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Ohashi T, Fukuzawa Y, Kakumu S (2007) Expression of Toll-like receptors in chronic hepatitis C virus infection. *J. Gastroenterol. Hepatol.*, 22:1627-1632.
31. Zhang Y, El-Far M, Dupuy FP, Abdel Hakeem M, He Z, Procopio FA, Shi Y, Haddad EK, Ancuta P, Sekaly R-P, Said EA (2016) HCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses. *Sci. Rep.*, 6: 29447.
32. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, van den Berg WB (2000) Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. *Arthritis Rheum.*, 43: 1951-1959.
33. Yang Q, Fu S, Wang J (2014) Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. *Arch. Virol.*, 159:2997-3003.
34. Verbeeck J, Maes P, Lemey P, Pybus OG, Wollants E, Song E, Nevens F, Fevery J, Delport W, Van der Merwe S, Van Ranst M (2006) Investigating the origin and spread of hepatitis C virus genotype 5a. *J. Virol.*, 80: 4220-4226.
35. Zimmermann R, Marcus U, Schäffer D, Leicht A, Wenz B, Nielsen S, Santos-Hövenier C, Ross RS, Stambouli O, Ratsch BA, Bannert N, Bock CT, Kücherer C, Hamouda O (2014) A multicenter sero-behavioral survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent-driven sampling. *BMC Public Health*, 14:845.
36. Rivera J, Garcia-Monforte A, Pineda A, Nunez-Cortes JM (1999) Arthritis in patients with chronic hepatitis C virus infection. *J. Rheumatol.*, 26: 420-424.
37. Taglione E, Vatteroni ML, Martini P, Galluzzo E, Lombardini F, Delle Sedie A, Bendinelli M, Pasero G, Bencivelli W, Riente L (1999) Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. *J. Rheumatol.*, 26:370-372.
38. El-Zanaty F, Way A (2009) Egypt Demographic and Health Survey 2008. Egyptian Ministry of Health (El-Zanaty and Associates and Macro International, Cairo), 431.

39. Mahmoud GA, Zayed HS, Sherif MM, Mostafa MM (2011) Characteristics of rheumatoid arthritis patients with concomitant hepatitis C virus infection. *The Egyptian Rheumatologist*, 33: 139 - 145.
40. Maillefert JF, Muller G, Falgarone G, Bour JB, Ratovohery D, Dougados M, Tavernier C, Breban M Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. *Ann Rheum Dis.*, 200; 61: 635–637.
41. Mencin A, Kluwe J, Schwabe R (2013) Toll-like receptors as targets in chronic liver diseases. *Gut.*, 58(5): 704-720
42. White PA, Li Z, Zhai X, Marinos G, Rawlinson WD (2000) Mixed viral infection identified using heteroduplex mobility analysis (HMA). *Virology*, 271: 382-389.
43. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Teraï K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. *Nat. Immunol.*, 5: 1061-1068.
44. Dehghan-Manshadi M, Hadinedoushan H, Amirbaigy M K, Zare F, Eslami G, Mirghanizade-Bafghi SA and Akhondi-Meybodi M (2015) Relative Expression of Toll-Like Receptors 2 and 7 mRNA in peripheral blood of patients with Hepatitis C. *Hepat. Mon.*, 15: e30427.